JP2005525302A - 化学的に修飾されたヒト成長ホルモンコンジュゲート - Google Patents

化学的に修飾されたヒト成長ホルモンコンジュゲート Download PDF

Info

Publication number
JP2005525302A
JP2005525302A JP2003545691A JP2003545691A JP2005525302A JP 2005525302 A JP2005525302 A JP 2005525302A JP 2003545691 A JP2003545691 A JP 2003545691A JP 2003545691 A JP2003545691 A JP 2003545691A JP 2005525302 A JP2005525302 A JP 2005525302A
Authority
JP
Japan
Prior art keywords
conjugate
hgh
group
poly
ethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003545691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525302A5 (enExample
Inventor
フィン，ロリー・エフ
リャオ，ウェイ
シーゲル，ネッド・アール
Original Assignee
ファルマシア・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルマシア・コーポレーション filed Critical ファルマシア・コーポレーション
Publication of JP2005525302A publication Critical patent/JP2005525302A/ja
Publication of JP2005525302A5 publication Critical patent/JP2005525302A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2003545691A 2001-11-20 2002-11-20 化学的に修飾されたヒト成長ホルモンコンジュゲート Pending JP2005525302A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006193577A Division JP2006321808A (ja) 2001-11-20 2006-07-14 化学的に修飾されたヒト成長ホルモンコンジュゲート

Publications (2)

Publication Number Publication Date
JP2005525302A true JP2005525302A (ja) 2005-08-25
JP2005525302A5 JP2005525302A5 (enExample) 2006-01-05

Family

ID=23295870

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003545691A Pending JP2005525302A (ja) 2001-11-20 2002-11-20 化学的に修飾されたヒト成長ホルモンコンジュゲート
JP2006193577A Pending JP2006321808A (ja) 2001-11-20 2006-07-14 化学的に修飾されたヒト成長ホルモンコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006193577A Pending JP2006321808A (ja) 2001-11-20 2006-07-14 化学的に修飾されたヒト成長ホルモンコンジュゲート

Country Status (25)

Country Link
EP (1) EP1453859A2 (enExample)
JP (2) JP2005525302A (enExample)
KR (2) KR20050044858A (enExample)
CN (1) CN1608079A (enExample)
AP (1) AP2004003050A0 (enExample)
AU (1) AU2002356990A1 (enExample)
BR (1) BR0214451A (enExample)
CA (1) CA2467731A1 (enExample)
CO (1) CO5580794A2 (enExample)
EA (2) EA008505B1 (enExample)
EC (1) ECSP045114A (enExample)
GE (1) GEP20063860B (enExample)
HR (1) HRP20040448A2 (enExample)
HU (1) HUP0500997A2 (enExample)
IL (1) IL162031A0 (enExample)
IS (1) IS7268A (enExample)
MA (1) MA27544A1 (enExample)
MX (1) MXPA04004809A (enExample)
NO (1) NO20042182L (enExample)
OA (1) OA13063A (enExample)
PL (1) PL374354A1 (enExample)
RS (1) RS53104A (enExample)
TN (1) TNSN04090A1 (enExample)
WO (1) WO2003044056A2 (enExample)
ZA (1) ZA200403907B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506096A (ja) * 2005-08-30 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー ペグ化成長ホルモンの液状調製物
JP2011516429A (ja) * 2008-04-03 2011-05-26 バイオスティード ジーン エクスプレッション テック． カンパニー リミテッド 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
JP2011529910A (ja) * 2008-07-31 2011-12-15 ファーマエッセンティア コーポレイション ペプチド−ポリマー共役体
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
WO2017047788A1 (ja) * 2015-09-18 2017-03-23 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
US11559567B2 (en) 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc NOVEL MONOFUNCTIONAL POLYETHYLENE GLYCOL ALDEHYDES
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
MXPA04006855A (es) * 2002-01-18 2005-04-19 Biogen Idec Inc Compuestos de polimeros de polialquileno y usos de los mismos.
GEP20074193B (en) 2002-09-09 2007-09-10 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
CN100580087C (zh) * 2003-10-10 2010-01-13 诺和诺德医疗保健公司 肽的缀合
CA2552043A1 (en) * 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
WO2006069220A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
MX2007002441A (es) * 2004-08-31 2007-05-04 Pharmacia & Upjohn Co Llc Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos.
GB2438982A (en) 2004-12-22 2007-12-12 Ambrx Inc Compostions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8080391B2 (en) * 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP1850878A2 (en) 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
ATE497975T1 (de) 2005-04-18 2011-02-15 Novo Nordisk As Il-21-varianten
ATE500215T1 (de) * 2005-11-08 2011-03-15 Ambrx Inc Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
EP1968635B1 (en) 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2008003750A2 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
WO2010030366A2 (en) * 2008-09-11 2010-03-18 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
CN102292349B (zh) 2009-01-22 2016-04-13 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
KR20250059541A (ko) 2014-11-18 2025-05-02 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
MA41957A (fr) * 2015-03-11 2018-02-28 Nektar Therapeutics Conjugués d'une fraction d'il-7 et d'un polymère
JP7524206B2 (ja) 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス １日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
EP0458064B1 (en) * 1990-05-04 1998-02-25 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE851925T1 (de) * 1995-09-21 2003-08-14 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
WO2000042175A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology Inc. Methods for making proteins containing free cysteine residues
EP1012184B1 (en) * 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
IL144361A0 (en) * 1999-01-29 2002-05-23 Hoffmann La Roche Gcsf conjugates
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506096A (ja) * 2005-08-30 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー ペグ化成長ホルモンの液状調製物
JP2011516429A (ja) * 2008-04-03 2011-05-26 バイオスティード ジーン エクスプレッション テック． カンパニー リミテッド 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
JP2011529910A (ja) * 2008-07-31 2011-12-15 ファーマエッセンティア コーポレイション ペプチド−ポリマー共役体
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
US11559567B2 (en) 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon
US12343381B2 (en) 2014-11-06 2025-07-01 Pharmaessentia Corporation Dosage regimen for pegylated interferon
WO2017047788A1 (ja) * 2015-09-18 2017-03-23 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
JPWO2017047788A1 (ja) * 2015-09-18 2018-07-05 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
US10842879B2 (en) 2015-09-18 2020-11-24 University Of Miyazaki Long-acting adrenomedullin derivative
JP6991569B2 (ja) 2015-09-18 2022-02-15 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
US11478551B2 (en) 2015-09-18 2022-10-25 University Of Miyazaki Long-acting adrenomedullin derivative
US12171836B2 (en) 2015-09-18 2024-12-24 University Of Miyazaki Long-acting adrenomedullin derivative

Also Published As

Publication number Publication date
GEP20063860B (en) 2006-06-26
RS53104A (sr) 2006-10-27
EP1453859A2 (en) 2004-09-08
BR0214451A (pt) 2006-05-30
JP2006321808A (ja) 2006-11-30
PL374354A1 (en) 2005-10-17
NO20042182L (no) 2004-08-11
EA200700431A1 (ru) 2008-02-28
CO5580794A2 (es) 2005-11-30
TNSN04090A1 (fr) 2006-06-01
CN1608079A (zh) 2005-04-20
MXPA04004809A (es) 2004-08-11
OA13063A (en) 2006-11-10
CA2467731A1 (en) 2003-05-30
ECSP045114A (es) 2004-07-23
WO2003044056A3 (en) 2003-08-21
IS7268A (is) 2004-05-17
AP2004003050A0 (en) 2004-06-30
HUP0500997A2 (en) 2007-11-28
EA008505B1 (ru) 2007-06-29
KR20050044858A (ko) 2005-05-13
KR20070072924A (ko) 2007-07-06
IL162031A0 (en) 2005-11-20
MA27544A1 (fr) 2005-10-03
AU2002356990A1 (en) 2003-06-10
EA200400565A1 (ru) 2005-06-30
WO2003044056A2 (en) 2003-05-30
HRP20040448A2 (en) 2006-02-28
ZA200403907B (en) 2007-12-27

Similar Documents

Publication Publication Date Title
JP2005525302A (ja) 化学的に修飾されたヒト成長ホルモンコンジュゲート
US20030171285A1 (en) Chemically-modified human growth hormone conjugates
EP1715887B1 (en) N-terminally monopegylated human growth hormone conjugates, process for their preparation, and use thereof
NL1029828C2 (nl) Conjugaten van glycerol-vertakt polyethyleenglycol en menselijk groeihormoon, werkwijzen voor de bereiding daarvan en werkwijzen voor gebruik daarvan.
NL1024831C2 (nl) N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan.
US20040038892A1 (en) Chemically-modified human growth hormone conjugates
US20090203589A1 (en) Chemically modified human growth hormone receptor antagonist conjugates
HK1072058A (en) Chemically-modified human growth hormone conjugates
HK1104913A (en) Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050711

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20050711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050711

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20050809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060714

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20060808

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20060901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070515